BAJAJ BROKING

Notification close image
No new Notification messages
card image
Smartworks Coworking Spaces IPO is Open!
Apply for the Smartworks Coworking Spaces IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

1153

500660

GLAXO

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GLAXOSMITHKLINE PHARMA LT performance

Today’s low

Today’s high

₹ 3246.00 ₹ 3319.90
₹ 3251.90

52 week low

52 week high

₹ 1921.00 ₹ 3515.70
₹ 3251.90

Open Price

₹ 3309.10

Prev. Close

₹ 3309.00

Volume (Shares)

45314.00

Total traded value

₹ 1473.56

Upper Circuit

₹ 3970.80

Lower Circuit

₹ 2647.20

info

GLAXOSMITHKLINE PHARMA LT Share Price Update

As of the latest trading session, GLAXOSMITHKLINE PHARMA LT share price is currently at ₹ 3251.9, which is down by ₹ -57.10 from its previous closing. Today, the stock has fluctuated between ₹ 3246.00 and ₹ 3319.90. Over the past year, GLAXOSMITHKLINE PHARMA LT has achieved a return of 29.42 %. In the last month alone, the return has been -2.61 %. Read More...

Investment Returns

Over 1 Month -2.61% Over 3 Months 23.68% Over 6 Months 49.84% Over 1 Year 29.42%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GLAXOSMITHKLINE PHARMA LT fundamentals


  • Market cap (Cr)

    55,089.10

  • P/E Ratio (TTM)

    60.84

  • Beta

    0.67

  • Book Value / share

    115.06

  • Return on equity

    49.23%

  • EPS (TTM)

    51.09

  • Dividend yield

    1.64%

  • Net profit/quarter (Cr)

    260.14

info icon alternate text
  • Market cap (Cr)

    55,057.80

  • P/E Ratio (TTM)

    60.84

  • Beta

    0.63

  • Book Value / share

    115.06

  • Return on equity

    49.23%

  • EPS (TTM)

    51.09

  • Dividend yield

    1.64%

  • Net profit/quarter (Cr)

    260.14

info icon alternate text

GLAXOSMITHKLINE PHARMA LT Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 966.08
Operating Expense 650.64
Net Profit 260.14
Net Profit Margin (%) 26.92
Earnings Per Share (EPS) 15.35
EBITDA 370.20
Effective Tax Rate (%) 26.70
Particulars DEC 2024 (Values in Cr)
Revenue 946.36
Operating Expense 675.07
Net Profit 228.58
Net Profit Margin (%) 24.15
Earnings Per Share (EPS) 13.49
EBITDA 325.24
Effective Tax Rate (%) 25.38
Particulars SEP 2024 (Values in Cr)
Revenue 1000.05
Operating Expense 698.23
Net Profit 248.69
Net Profit Margin (%) 24.86
Earnings Per Share (EPS) 14.45
EBITDA 355.83
Effective Tax Rate (%) 26.57
Particulars JUN 2024 (Values in Cr)
Revenue 811.00
Operating Expense 598.36
Net Profit 181.65
Net Profit Margin (%) 22.39
Earnings Per Share (EPS) 10.72
EBITDA 265.27
Effective Tax Rate (%) 26.89
Particulars MAR 2024 (Values in Cr)
Revenue 910.87
Operating Expense 674.43
Net Profit 193.08
Net Profit Margin (%) 21.19
Earnings Per Share (EPS) 11.29
EBITDA 287.58
Effective Tax Rate (%) 28.14
Particulars MAR 2025 (Values in Cr)
Revenue 3723.49
Operating Expense 2622.29
Net Profit 919.06
Net Profit Margin (%) 24.68
Earnings Per Share (EPS) 54.01
EBITDA 1316.54
Effective Tax Rate (%) 26.38
Particulars MAR 2024 (Values in Cr)
Revenue 3407.25
Operating Expense 2578.08
Net Profit 584.69
Net Profit Margin (%) 17.16
Earnings Per Share (EPS) 40.83
EBITDA 880.52
Effective Tax Rate (%) 27.73
Particulars MAR 2023 (Values in Cr)
Revenue 3216.34
Operating Expense 2484.50
Net Profit 607.75
Net Profit Margin (%) 18.89
Earnings Per Share (EPS) 35.88
EBITDA 899.95
Effective Tax Rate (%) 27.35
Particulars MAR 2022 (Values in Cr)
Revenue 3217.51
Operating Expense 2531.85
Net Profit 1690.53
Net Profit Margin (%) 52.54
Earnings Per Share (EPS) 99.79
EBITDA 843.63
Effective Tax Rate (%) 51.31
Particulars MAR 2021 (Values in Cr)
Revenue 2920.47
Operating Expense 2404.83
Net Profit 357.57
Net Profit Margin (%) 12.24
Earnings Per Share (EPS) 21.10
EBITDA 535.36
Effective Tax Rate (%) 36.74
Particulars MAR 2025 (Values in Cr)
Book Value / Share 115.19
ROE % 49.75
ROCE % 59.29
Total Debt to Total Equity 0.01
EBITDA Margin 35.42
Particulars MAR 2024 (Values in Cr)
Book Value / Share 104.93
ROE % 37.32
ROCE % 44.97
Total Debt to Total Equity 0.01
EBITDA Margin 28.42
Particulars MAR 2023 (Values in Cr)
Book Value / Share 102.79
ROE % 27.73
ROCE % 33.92
Total Debt to Total Equity 0.01
EBITDA Margin 27.89
Particulars MAR 2022 (Values in Cr)
Book Value / Share 157.19
ROE % 81.31
ROCE % 32.55
Total Debt to Total Equity 0.01
EBITDA Margin 25.53
Particulars MAR 2021 (Values in Cr)
Book Value / Share 87.26
ROE % 28.86
ROCE % 32.43
Total Debt to Total Equity 0.01
EBITDA Margin 24.23
Particulars MAR 2025 (Values in Cr)
Book Value / Share 115.06
ROE % 49.23
ROCE % 58.72
Total Debt to Total Equity 0.01
EBITDA Margin 35.36
Particulars MAR 2024 (Values in Cr)
Book Value / Share 105.31
ROE % 36.83
ROCE % 44.44
Total Debt to Total Equity 0.01
EBITDA Margin 28.60
Particulars MAR 2023 (Values in Cr)
Book Value / Share 103.48
ROE % 27.43
ROCE % 33.60
Total Debt to Total Equity 0.01
EBITDA Margin 28.08
Particulars MAR 2022 (Values in Cr)
Book Value / Share 158.06
ROE % 80.45
ROCE % 32.11
Total Debt to Total Equity 0.01
EBITDA Margin 25.83
Particulars MAR 2021 (Values in Cr)
Book Value / Share 88.37
ROE % 28.49
ROCE % 32.10
Total Debt to Total Equity 0.01
EBITDA Margin 24.24
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1403.51
Total Assets 4108.06
Total Liabilities 4108.06
Total Equity 1951.31
Share Outstanding 169406034
Price to Book Ratio 25.01
Return on Assets (%) 22.57
Return on Capital (%) 47.54
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1063.21
Total Assets 3556.61
Total Liabilities 3556.61
Total Equity 1777.63
Share Outstanding 169406034
Price to Book Ratio 18.45
Return on Assets (%) 16.58
Return on Capital (%) 33.19
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1155.92
Total Assets 3326.58
Total Liabilities 3326.58
Total Equity 1741.27
Share Outstanding 169406034
Price to Book Ratio 12.80
Return on Assets (%) 18.35
Return on Capital (%) 35.07
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2484.50
Total Assets 4633.27
Total Liabilities 4633.27
Total Equity 2662.95
Share Outstanding 169406034
Price to Book Ratio 10.52
Return on Assets (%) 36.57
Return on Capital (%) 63.64
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1157.96
Total Assets 3114.64
Total Liabilities 3114.64
Total Equity 1478.25
Share Outstanding 169406034
Price to Book Ratio 16.30
Return on Assets (%) 11.49
Return on Capital (%) 24.23
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1400.88
Total Assets 4100.93
Total Liabilities 4100.93
Total Equity 1949.23
Share Outstanding 169406034
Price to Book Ratio 25.01
Return on Assets (%) 22.41
Return on Capital (%) 47.15
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1061.19
Total Assets 3547.80
Total Liabilities 3547.80
Total Equity 1784.09
Share Outstanding 169406034
Price to Book Ratio 18.45
Return on Assets (%) 16.48
Return on Capital (%) 32.77
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1150.73
Total Assets 3327.69
Total Liabilities 3327.69
Total Equity 1752.99
Share Outstanding 169406034
Price to Book Ratio 12.80
Return on Assets (%) 18.26
Return on Capital (%) 34.67
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2479.11
Total Assets 4622.59
Total Liabilities 4622.59
Total Equity 2677.61
Share Outstanding 169406034
Price to Book Ratio 10.52
Return on Assets (%) 36.57
Return on Capital (%) 63.14
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1157.67
Total Assets 3097.07
Total Liabilities 3097.07
Total Equity 1497.11
Share Outstanding 169406034
Price to Book Ratio 16.30
Return on Assets (%) 11.54
Return on Capital (%) 23.88
Particulars MAR 2025 (Values in Cr)
Net Income 1255.18
Cash from Operations 1371.60
Cash from Investing -45.80
Cash from Financing -769.42
Net change in Cash 474.67
Free Cash Flow 1394.62
Particulars MAR 2024 (Values in Cr)
Net Income 959.80
Cash from Operations 975.69
Cash from Investing 8.71
Cash from Financing -561.49
Net change in Cash 29.23
Free Cash Flow 1006.91
Particulars MAR 2023 (Values in Cr)
Net Income 841.49
Cash from Operations 755.74
Cash from Investing 807.85
Cash from Financing -1543.32
Net change in Cash -251.24
Free Cash Flow 799.78
Particulars MAR 2022 (Values in Cr)
Net Income 2475.64
Cash from Operations 959.03
Cash from Investing -405.50
Cash from Financing -524.24
Net change in Cash -119.00
Free Cash Flow 993.67
Particulars MAR 2021 (Values in Cr)
Net Income 723.09
Cash from Operations 743.20
Cash from Investing 418.02
Cash from Financing -695.55
Net change in Cash 300.37
Free Cash Flow 787.42
Particulars MAR 2025 (Values in Cr)
Net Income 1243.74
Cash from Operations 1360.95
Cash from Investing -36.53
Cash from Financing -769.42
Net change in Cash 474.07
Free Cash Flow 1383.97
Particulars MAR 2024 (Values in Cr)
Net Income 952.65
Cash from Operations 971.05
Cash from Investing 14.96
Cash from Financing -561.49
Net change in Cash 32.40
Free Cash Flow 1002.27
Particulars MAR 2023 (Values in Cr)
Net Income 837.48
Cash from Operations 757.61
Cash from Investing 805.19
Cash from Financing -1544.17
Net change in Cash -251.04
Free Cash Flow 801.65
Particulars MAR 2022 (Values in Cr)
Net Income 2470.04
Cash from Operations 968.00
Cash from Investing -419.66
Cash from Financing -524.24
Net change in Cash -124.11
Free Cash Flow 1002.64
Particulars MAR 2021 (Values in Cr)
Net Income 722.33
Cash from Operations 760.11
Cash from Investing 407.56
Cash from Financing -695.55
Net change in Cash 306.87
Free Cash Flow 804.33
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.19 32.03 1.98 277.34 34.11 / 77.70
BLISS GVS PHARMA LTD 155.40 19.45 1.56 1638.62 105.05 / 184.95
CIPLA LTD 1491.80 23.42 3.86 120493.85 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 356.25 13.64 2.88 1048.48 189.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.19 92.79 5.71 277.34 34.11 / 77.70
AMRUTAJAN HEALTH LTD 717.40 40.81 6.35 2074.05 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 9296.00 132.76 30.16 23240.00 6222.35 / 10653.05
BLISS GVS PHARMA LTD 155.40 23.76 1.54 1638.62 105.05 / 184.95

GLAXOSMITHKLINE PHARMA LT Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
3251.90 -1.72 redarrow
red-green-graph indicator
10 Bearish
6 Bullish
  • 5 Days 3294.40
  • 26 Days 3265.20
  • 10 Days 3297.90
  • 50 Days 3159.90
  • 12 Days 3297.50
  • 100 Days 2966.80
  • 20 Days 3284.40
  • 200 Days 2749.30
3306.37 PIVOT

First Support

3268.73

First Resistance

3346.63

Second Support

3228.47

Second Resistance

3384.27

Third Support

3190.83

Third Resistance

3424.53

RSI

53.90

ADX

17.24

MACD

32.30

Williams % R

-55.19

Commodity Channel Index (CCI)

13.92

Date

2025-07-09

Week

40908.00

Same Day

47770.00

Month

71735.00

1 Year

0.68

3 Year

0.49

Over 1 Month

-2.61%

down

Over 1 Year

29.42%

down

Over 3 Months

23.68%

down

Over 3 Years

30.19%

down

Over 6 Months

49.84%

down

Over 5 Years

17.54%

down

GLAXOSMITHKLINE PHARMA LT shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
12.69%
Promoter Holdings
75.0%
FII
4.51%
DII
7.78%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Glaxo Group Limited 6.09705E7 (35.99%) Shareholding of Promoter and Promoter Group
Glaxosmithkline Pte Limited 4.7604024E7 (28.1%) Shareholding of Promoter and Promoter Group
Eskaylab Limited 1.176E7 (6.94%) Shareholding of Promoter and Promoter Group
Burroughs Wellcome International Limited 6720000.0 (3.97%) Shareholding of Promoter and Promoter Group
Sbi Nifty Midcap 150 Index Fund 2159437.0 (1.27%) Public Shareholding
Life Insurance Corporation Of India - P & Gs Fund 2010665.0 (1.19%) Public Shareholding

News

Left Arrow
Right Arrow

GLAXOSMITHKLINE PHARMA LT corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
30 Jun 2023 32.0 Final 30 Jun 2023 Equity shares
07 Jul 2022 30.0 Final 08 Jul 2022 Equity shares
07 Jul 2022 60.0 Special 08 Jul 2022 Equity shares
19 Jul 2021 30.0 Final 20 Jul 2021 Equity shares
17 Jul 2020 20.0 Final 20 Jul 2020 Equity shares
17 Jul 2020 20.0 Special 20 Jul 2020 Equity shares
11 Jul 2019 20.0 Final 15 Jul 2019 Equity shares
13 Jul 2018 35.0 Final 17 Jul 2018 Equity shares
14 Jul 2017 30.0 Final 18 Jul 2017 Equity shares
15 Jul 2016 50.0 Final 19 Jul 2016 Equity shares
23 Jul 2015 62.5 Final 25 Jul 2015 Equity shares
03 Apr 2014 50.0 Final 07 Apr 2014 Equity shares
04 Apr 2013 50.0 Final 08 Apr 2013 Equity shares
29 Mar 2012 45.0 Final 02 Apr 2012 Equity shares
14 Mar 2011 40.0 Final 16 Mar 2011 Equity shares
10 Mar 2010 30.0 Final 12 Mar 2010 Equity shares
18 Mar 2009 22.0 Final 20 Mar 2009 Equity shares
18 Mar 2009 18.0 Special 20 Mar 2009 Equity shares
02 Apr 2008 18.0 Final 04 Apr 2008 Equity shares
02 Apr 2008 18.0 Special 04 Apr 2008 Equity shares
14 Mar 2007 17.0 Final 16 Mar 2007 Equity shares
14 Mar 2007 14.0 Special 16 Mar 2007 Equity shares
Ex-Date Ex-Bonus Ratio
13 Sep 2018 11 Sep 2018 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
31 May 2024 32.0 Final 31 May 2024 Equity shares
30 Jun 2023 32.0 Final 30 Jun 2023 Equity shares
07 Jul 2022 30.0 Final 08 Jul 2022 Equity shares
07 Jul 2022 60.0 Special 08 Jul 2022 Equity shares
19 Jul 2021 30.0 Final 20 Jul 2021 Equity shares
17 Jul 2020 20.0 Final 20 Jul 2020 Equity shares
17 Jul 2020 20.0 Special 20 Jul 2020 Equity shares
11 Jul 2019 20.0 Final 15 Jul 2019 Equity shares
13 Jul 2018 35.0 Final 17 Jul 2018 Equity shares
14 Jul 2017 30.0 Final 18 Jul 2017 Equity shares
15 Jul 2016 50.0 Final 19 Jul 2016 Equity shares
23 Jul 2015 62.5 Final 25 Jul 2015 Equity shares
03 Apr 2014 50.0 Final 07 Apr 2014 Equity shares
04 Apr 2013 50.0 Final 08 Apr 2013 Equity shares
29 Mar 2012 45.0 Final 02 Apr 2012 Equity shares
14 Mar 2011 40.0 Final 16 Mar 2011 Equity shares
10 Mar 2010 30.0 Final 12 Mar 2010 Equity shares
18 Mar 2009 22.0 Final 20 Mar 2009 Equity shares
18 Mar 2009 18.0 Special 20 Mar 2009 Equity shares
02 Apr 2008 18.0 Final 04 Apr 2008 Equity shares
02 Apr 2008 18.0 Special 04 Apr 2008 Equity shares
14 Mar 2007 17.0 Final 16 Mar 2007 Equity shares
14 Mar 2007 14.0 Special 16 Mar 2007 Equity shares
Ex-Date Ex-Bonus Ratio
13 Sep 2018 11 Sep 2018 1:1
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

GLAXOSMITHKLINE PHARMA LT Share Price

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924. The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001.

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together. The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India. The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

The Company's portfolio includes General Medicines, Vaccines and Specialty medicines that help prevent and treat disease. Their prescription medicines range across therapeutic areas, such as Anti-Infectives, Dermatology, Gynaecology, Diabetes, Oncology, Cardiovascular Disease and Respiratory Diseases. They also offer a range of vaccines, for the prevention of Hepatitis A, Hepatitis B, Invasive Disease caused by H, Influenza, Chickenpox, Diphtheria, Pertussis, Tetanus, Rotavirus, Cervical Cancer and Others. They have two manufacturing units in India, located at Nashik and Thane. Also, they have a clinical development centre in Bangalore.

During year 1956, the Company began primary production of vaccines at Worli. In the year 1960, the company started manufacturing Infant foods at milk drying plant at Aligarh. They also opened manufacturing facility for pharmaceuticals in Mumbai. In 1961, the Company started manufacturing Vitamin A and Betamethasone at new plant at Thane using imported raw materials. The Company registered as a limited company in the year 1968. Also, they introduced the Animal health products.

In the year 1971, the company built the Research & development laboratory at Thane. Also, they relocated the SmithKline & French plant from Mumbai to Bangalore. In the year 1983, they commissioned the Nashik factory. SmithKline & Beecham became a public limited company under the new name of Eskayef Ltd in the year 1984 and one new Plant was set up in Mysore for manufacture of bulk drugs. In the year 1985, the company's second basic drugs factory was inaugurated at Ankleshwar, Gujarat. In the year 1986, the company launched joint venture projects Vegepro Foods and Feeds Ltd and K G Gluco Biols.

In the year 1988, the company commenced the production of bulk drug Ranitidine at Ankleshwar. Also, they started a joint venture project with Hindustan Foods Ltd for the manufacture of extruded foods at Usgao, Goa.

In the year 1989, the company commenced their Zinetac production at Nashik. In the year 1990, the production of the bulk drug, cephalexin was commenced at Ankleshwar and the salbutamol inhalers at Nashik. Glaxo rated amongst the first five of India's most respected companies (4th place), in a survey by Businessworld magazine. An agreement was signed with the Council of Scientific and Industrial Research (CSIR) during 1991. In the year 1992, the company sold their trade investments in Vegepro and Feeds Ltd. In the year 1993, they sold their investment in Hindustan Foods Ltd and Dempo Dairy Industries Ltd. Cetzine, a second-generation anti-histamine and research product of UCB Pharma (Belgium) was launched under a co-marketing agreement. In the same year Glaxo received recognition from the Ministry of Commerce as an export house.

In the year 1994, the company sold their Family Products Division to H J Heinz for a sum of Rs 210 crore. The Mysore plant received ISO 9002 certification and the new Iodex plant was inaugurated in Bangalore. In the year 1995, they inaugurated the government approved state-of-the-art Pharmacy Research & Development Centre (PR&D) at Thane to cater to the unmet medical needs and to exploit local commercial opportunities.

In the year 1998, the company acquired Biddle Sawyer Group of Companies, which was struggled in the year before. In the year 2000, Agrivet Farm Care (AFC) tied up with Merial, the world's largest Animal Health Company, to market poultry vaccines. The company ranked 6th in 'Business Today' - Stern Stewart & Co. listing of India's best Wealth Creator Companies and also the launched Seretide for Asthma. The merger of SmithKline Beecham Pharmaceuticals (India) Ltd into Glaxo India Limited was completed. Businessworld and the Indian Market Research Bureau (IMRB) named GlaxoSmithKline as India's most respected Pharmaceutical Company in a survey in the year 2003. During the year, the company launched Cetzine (Cetirizine; anti-histamine), Zimig (terbinafine; anti-infective), CCM (calcium citrate maleate; nutritional), Cobadex CZS (multivitamin with trace elements).

In the year 2004, the company launched Priorix (measles, mumps, rubella vaccine). In the year 2005, the company launched oral contraceptives: Elogen (desogestrel and ethinylestradiol) and Zerogen (progesterone only pill). They entered into the diabetes therapeutic segment with the launch of Windia (rosiglitazone) and Windamet (rosiglitazone and metformin). In the year 2006, the company made an in-licensing alliance with Eisai Pharmaceuticals, Japan and launched Parit (rabeprazole; gastrointestinal therapy area). Also, GlaxoSmithKline divested their Agrivet Farm Care (AFC) animal health business. In the year 2007, the company launched Carzec (carvedilol) and Zemetril (cefprozil). In March 2007, the company opened new Medicinal Chemistry Laboratory at their R&D facility in Singapore. Also, they divested their other peripheral business of fine chemicals with consideration of Rs 240 crore on slump sale basis to Thermo Electron LLS India Private Ltd.

In the year 2008, the company increased the installed capacity of Tablets and Capsules from 6750 million nos to 6950 million nos. They increased the production capacity of Solids including Powders and Ointments from 1550 tonnes to 2225 tonnes. In January 2008, the company launched two of their new innovative Diphtheria, Tetanus and acellular Pertussis (DTP) vaccines, such as Boostrix and Infanrix. Also the company in well positioned to launch the breast cancer drug, Tykerb and the rotavirus vaccine, Rotarix during the year. Also, they rolled out three new Business Partnering initiatives during the year.

In the year 2009, the company launched new products, namely Benitec A (Olmesatan in combination with Amilodipine) in Cardiology, Dermocalm (Calamine lotion) in Dermatology, Ventorlin CFC free inhaler (Salbutamol) in Respiratory and Esblanem (Meropenem) in Antibiotic segments. Their Nashik site commenced manufacture and supply of Albendazole tablets to WHO for the Lymphatic Filriasis eradication programme.

In the year 2010, the company increased the installed capacity of Solids including Powders and Ointments from 2225 tonnes to 2600 tonnes. They launched some new products namely, Mycamine inj (Micafungin) in-licensed from Astellas and Parit D capsules (Rabeprazole in combination with Domperidone) in-licensed from Eisai. Cefspan (Cefixime - oral antibiotic) was relaunched with good success. Other branded generics launched during the year were Modvate 3 cream (Beclomethasone in combination with Clotrimazole and Neomycin) and Modvate AF cream (Beclomethasone in combination witr Clotrimazole) in Dermatology. Formulations of Atorvastatin and Rosuvastatin tablets were launchec in Cardiology under the brand names 'Lilo' and 'Rosutec' respectively. The combination of Paracetamol with Tramadol was launched under the brand name 'Calpol T'.

In the year 2011, the company foray into branded generics market. Zobactin is ranked as the No. 2 brand (Dec MAT 2011, H.S.A) in a market which has more than 56 brands of Piperacillin+Tazobactum. In the Meropenem market, Esblanem is ranked at 6th position (Dec MAT 2011, H.S.A). After the successful launch of Tykerb in 2008, they expanded their presence further by introducing two new segments, Kidney Cancer and Hematology with launch of Votrient and Revolade.

In 2012, the company Introduces Metered Dose Inhaler with dose counter. On 30 September 2015, the company announced the completion of its transaction with Novartis Healthcare Pvt. Ltd. (Novartis India) whereby the company has acquired Novartis' vaccines business and divested its marketed oncology portfolio to Novartis India. This follows a global transaction between GlaxoSmithKline plc, UK (GSK) and Novartis AG, Switzerland (Novartis) which was completed in March 2015 on the same basis. The acquisition of the vaccines business of Novartis provides GSK with an exciting opportunity to build an even stronger, sustainable global vaccines business. The transaction will enhance GSK's vaccines portfolio and bring together its expertise in virology, bacterial infection and technological platforms to deliver a reliable supply of high quality vaccines.

During the quarter ended 30 September 2016, the company successfully launched Priorix-Tetra, a combined measles, mumps, rubella and varicella vaccine.

During the quarter ended 31 December 2016, the company successfully launched EnteroPlus, a probiotic food supplement. The company also restored the manufacturing of a key brand, Neosporin, an antibiotic used to treat minor wounds.

During the quarter ended 30 September 2017, the company announced its intention to dispose of its surplus land at Thane in Maharashtra to Oberoi Realty for Rs 555 crore subject to receipt of all regulatory and statutory approvals, as well as various conditions as agreed with the purchaser.

During the quarter ended 31 December 2017, the company received the money in advance towards disposal of Thane land. During the quarter ended 31 March 2018, the company successfully launched Biopatch, a hydrophilic wound dressing that is used to cover a wound caused by the use of percutaneous medical devices. Biopatch is recommended in skin sterilization protocol to reduce the incidence of CRBSI. Patients at risk of CRBSI are the ones in ICUs, those receiving chemotherapy and patients undergoing dialysis through catheters.

The Company has allotted fully paid up equity shares of Rs 10 each during the quarter ended 30th September 2018, pursuant to a bonus issue in ratio 1:1, as approved by the members through postal ballot. 8,47,03,017 Bonus shares have been issued by capitalization of profits transferred from general reserve.

The manufacturing facility for Eltroxin has commenced operation since 2019. In December 2019, the Company launched Menveo a Quadrivalent Meningococcal Conjugate Vaccine.

During FY2020,the company spent Rs 41 crore as capital expenditure, towards renovation of its corporate office into a modern workplace.

In September 2020, the Company launched tetravalent influenza flu vaccine, Fluarix Tetra to help combat influenza.

In June, 2021 Company launched the 'Nucala', first anti-IL5 drug, auto-injector device in India. It launched Trelegy Ellipta, the country's first single inhaler triple therapy (SITT) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) patients. It launched Augmentin ES deploying technology in reaching out to key specialists in ear, nose and throat (ENT) and Paediatrics practice.

Calpol+ with OPTIZORB formulation was launched in March 2023. The Company launched Shingrix, an adult vaccination for the prevention of Herpes Zoster and post-herpetic neuralgia (PHN) in 2024.

In 2025, Company has launched two new line extensions for Eltroxin-125 mcg & 37.5 mcg- and introduced innovative protective packaging with scavenger technology, ensuring consistent dosing & stability. Company has forayed into newer segments like emollients with Physiogel, which is now the fourth most prescribed emollient brand among Dermatologists. In FY2024-25, Company introduced T-Bact ointment 15g in a new Lami pack format and Becadexamin capsules were launched in a 60s HDPE pack format to improve efficiency.

Parent organization MNC Associate - Glaxo
NSE symbol GLAXO
Founded 1924
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

Glaxosmithkline Pharmaceuticals Ltd share price is for NSE ₹ 3,251.90 & for BSE ₹ 3,250.00 as on Jul 10 2025 03:30 PM.

What is the Market Cap of Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

The market cap of Glaxosmithkline Pharmaceuticals Ltd for NSE ₹ 55,089.15 & for BSE ₹ 55,056.96 as on Jul 10 2025 03:30 PM.

What is the 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Glaxosmithkline Pharmaceuticals Ltd for NSE is ₹ 3,515.70 and ₹ 1,921.00 and for BSE is ₹ 3,515.95 and ₹ 1,924.30.

What is 1 year return for Glaxosmithkline Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 29.42%.

What is the P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

As on Jul 10 2025 03:30 PM the price-to-earnings (PE) ratio for Glaxosmithkline Pharmaceuticals Ltd share is 60.84.

What is the PB ratio of Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

As on Jul 10 2025 03:30 PM, the price-to-book (PB) ratio for Glaxosmithkline Pharmaceuticals Ltd share is 115.06.

How to Buy Glaxosmithkline Pharmaceuticals Ltd Share?

Answer Field

You can trade in Glaxosmithkline Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Glaxosmithkline Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Glaxosmithkline Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Glaxosmithkline Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|